Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S, et al. Löwenberg B, et al. Among authors: zittoun r. J Clin Oncol. 1989 Sep;7(9):1268-74. doi: 10.1200/JCO.1989.7.9.1268. J Clin Oncol. 1989. PMID: 2475589 Clinical Trial.
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Willemze R, Jager U, Jehn U, Stryckmans P, Bury J, Suciu S, Solbu G, Zittoun R, Burghouts J, Löwenberg B, et al. Willemze R, et al. Among authors: zittoun r. Eur J Cancer Clin Oncol. 1988 Nov;24(11):1721-5. doi: 10.1016/0277-5379(88)90073-9. Eur J Cancer Clin Oncol. 1988. PMID: 3061827
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Löwenberg B, et al. Among authors: zittoun r. J Clin Oncol. 1998 Mar;16(3):872-81. doi: 10.1200/JCO.1998.16.3.872. J Clin Oncol. 1998. PMID: 9508168 Free article. Clinical Trial.
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P. Jehn U, et al. Among authors: zittoun r. Haematol Blood Transfus. 1990;33:277-84. doi: 10.1007/978-3-642-74643-7_50. Haematol Blood Transfus. 1990. PMID: 1691132 Clinical Trial.
EORTC Leukemia Group trials on acute myeloid leukemias: an overview.
Hayat M, Zittoun R, Strychmans P, Löwenberg B, Solbu G, Suciu S. Hayat M, et al. Among authors: zittoun r. Haematol Blood Transfus. 1990;33:271-6. doi: 10.1007/978-3-642-74643-7_49. Haematol Blood Transfus. 1990. PMID: 2182421 Clinical Trial. No abstract available.
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
De Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, Solbu G, Muus P. De Witte T, et al. Among authors: zittoun r. Ann Hematol. 1996 Mar;72(3):119-24. doi: 10.1007/s002770050148. Ann Hematol. 1996. PMID: 8766252 Clinical Trial.
425 results